Equities Analysts Issue Forecasts for Nkarta FY2025 Earnings

Nkarta, Inc. (NASDAQ:NKTX - Free Report) - Equities research analysts at HC Wainwright increased their FY2025 EPS estimates for Nkarta in a research note issued to investors on Thursday, May 15th. HC Wainwright analyst E. Bodnar now anticipates that the company will post earnings per share of ($1.21) for the year, up from their previous estimate of ($1.29). HC Wainwright has a "Buy" rating and a $18.00 price target on the stock. The consensus estimate for Nkarta's current full-year earnings is ($1.70) per share. HC Wainwright also issued estimates for Nkarta's Q4 2025 earnings at ($0.27) EPS, FY2026 earnings at ($1.43) EPS, FY2027 earnings at ($1.77) EPS, FY2028 earnings at ($1.51) EPS and FY2029 earnings at ($0.95) EPS.

Nkarta (NASDAQ:NKTX - Get Free Report) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($0.43) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.44) by $0.01.

A number of other research analysts have also recently weighed in on the company. Needham & Company LLC lowered their price objective on Nkarta from $11.00 to $10.00 and set a "buy" rating on the stock in a research report on Thursday. William Blair reaffirmed a "market perform" rating on shares of Nkarta in a report on Thursday. Finally, Stifel Nicolaus dropped their price target on shares of Nkarta from $15.00 to $14.00 and set a "buy" rating for the company in a research report on Thursday, March 27th. One investment analyst has rated the stock with a hold rating, five have given a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat, Nkarta presently has an average rating of "Buy" and a consensus target price of $14.67.

Nkarta Trading Up 1.2%

NKTX opened at $1.74 on Monday. The firm's 50 day simple moving average is $1.79 and its two-hundred day simple moving average is $2.19. The company has a market capitalization of $123.47 million, a PE ratio of -0.93 and a beta of 0.81. Nkarta has a 1-year low of $1.31 and a 1-year high of $8.23.

Institutional Investors Weigh In On Nkarta

Hedge funds have recently modified their holdings of the business. Invesco Ltd. bought a new position in Nkarta in the fourth quarter worth about $30,000. Sequoia Financial Advisors LLC bought a new position in shares of Nkarta during the 4th quarter worth approximately $31,000. China Universal Asset Management Co. Ltd. purchased a new stake in Nkarta during the fourth quarter valued at approximately $37,000. Wealth Enhancement Advisory Services LLC acquired a new stake in Nkarta in the first quarter valued at approximately $32,000. Finally, ProShare Advisors LLC acquired a new stake in Nkarta in the fourth quarter valued at approximately $45,000. Hedge funds and other institutional investors own 80.54% of the company's stock.

Nkarta Company Profile

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.